Hikma Pharmaceutic (OTCMKTS:HKMPF) has been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company.
Several equities analysts have weighed in on HKMPF shares. Zacks Investment Research downgraded Hikma Pharmaceutic from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. ValuEngine raised Hikma Pharmaceutic from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, Jefferies Group downgraded Hikma Pharmaceutic from a “hold” rating to an “underperform” rating in a research report on Wednesday, January 10th.
Hikma Pharmaceutic (OTCMKTS HKMPF) opened at $12.85 on Monday. Hikma Pharmaceutic has a 1 year low of $12.40 and a 1 year high of $27.50.
Hikma Pharmaceutic Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.